Up to 19% of HNSCC also overexpress the human epidermal growth factor receptor 2 (HER2) gene, thereby revealing an interesting opportunity to examine anti-EGFR and anti-HER2 dual treatment synergy to reduce HNSCC tumor burden. The gene discussed is EGFR; the disease is neoplasm.